Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
NCT ID: NCT00690313
Last Updated: 2019-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
22 participants
INTERVENTIONAL
2008-08-31
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study we compare the efficacy of Vigamox eye drops (antibiotic)starting 3 days prior to the injection versus 1 day prior to intravitreal injection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections
NCT02951351
Using Device Delivering Ophthalmic Solution in a Spray Form Instead of Eye Drops
NCT00565630
Bioequivalence of Eye Drops and Spray Administration of Vigamox
NCT00666042
Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period
NCT07090044
Post Intravitreal Injection Topical NSAID vs. Patching
NCT03918590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
Vigamox
eye drops 3 times day either 1 or 3 days prior to intravitreal injection
Arm 2
Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
Vigamox
eye drops 3 times day either 1 or 3 days prior to intravitreal injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vigamox
eye drops 3 times day either 1 or 3 days prior to intravitreal injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
21 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Illinois Retina Associates
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kourous A Rezaei, MD
Role: PRINCIPAL_INVESTIGATOR
Illinois Retina Associates SC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Illinois Retina Associates
Harvey, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Vig508
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.